复发性RhoGAP基因融合CLDN18-ARHGAP26促进弥漫型胃癌中RHOA活化及黏着斑激酶与YAP-TEAD信号传导
本研究构建了可诱导表达CLDN18-ARHGAP26融合的转基因小鼠模型,并用其胃类器官评估该融合的致癌活性及对RHOA通路的影响。结果显示融合表达诱导印戒细胞形成,与Trp53缺失协同转化胃细胞,促进RHOA活化及FAK和YAP通路激活,联合抑制FAK和YAP/TEAD可显著阻断肿瘤生长。
要点
- CLDN18-ARHGAP26融合在胃类器官中诱导印戒细胞形成,与Trp53缺失协同转化胃细胞。
- 该融合促进RHOA活化,并激活FAK和YAP下游效应信号。
- 联合抑制FAK和YAP/TEAD可显著阻断肿瘤生长。
核心结论
- CLDN18-ARHGAP26融合是功能获得性弥漫型胃癌癌基因,导致RHOA活化及FAK和YAP信号激活。
- 作者认为需进一步评估新兴FAK和YAP-TEAD抑制剂用于这些致命癌症。
研究设计与样本
- 构建LSL-CLDN18-ARHGAP26融合敲入Col1A1位点的转基因小鼠模型,其表达可由Cre重组酶诱导。
- 利用该模型生成的类器官评估融合的致癌活性及其对RHOA通路的生化效应和下游细胞生物学效应。
主要发现
- 在胃类器官中诱导CLDN18-ARHGAP26表达可形成印戒细胞,为弥漫型胃癌特征性表现。
- CLDN18-ARHGAP26与Trp53缺失协同转化胃细胞。
- CLDN18-ARHGAP26促进RHOA活化及下游效应信号。
- 该融合促进黏着斑激酶(FAK)激活并诱导YAP通路。
- 联合抑制FAK和YAP/TEAD可显著阻断肿瘤生长。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Genomic studies of gastric cancer have identified highly recurrent genomic alterations impacting RHO signalling, especially in the diffuse gastric cancer (DGC) histological subtype. Among these alterations are interchromosomal translations leading to the fusion of the adhesion protein CLDN18 and RHO regulator ARHGAP26. It remains unclear how these fusion constructs impact the activity of the RHO pathway and what is their broader impact on gastric cancer development. Herein, we developed a model to allow us to study the function of this fusion protein in the pathogenesis of DGC and to identify potential therapeutic targets for DGC tumours with these alterations. DESIGN: We built a transgenic mouse model with LSL-CLDN18-ARHGAP26 fusion engineered into the Col1A1 locus where its expression can be induced by Cre recombinase. Using organoids generated from this model, we evaluated its oncogenic activity and the biochemical effects of the fusion protein on the RHOA pathway and its downstream cell biological effects in the pathogenesis of DGC. RESULTS: We demonstrated that induction of CLDN18-ARHGAP26 expression in gastric organoids induced the formation of signet ring cells, characteristic features of DGC and was able to cooperatively transform gastric cells when combined with the loss of the tumour suppressor geneTrp53. CLDN18-ARHGAP26 promotes the activation of RHOA and downstream effector signalling. Molecularly, the fusion promotes activation of the focal adhesion kinase (FAK) and induction of the YAP pathway. A combination of FAK and YAP/TEAD inhibition can significantly block tumour growth. CONCLUSION: These results indicate that the CLDN18-ARHGAP26 fusion is a gain-of-function DGC oncogene that leads to activation of RHOA and activation of FAK and YAP signalling. These results argue for further evaluation of emerging FAK and YAP-TEAD inhibitors for these deadly cancers.
引用
- Zhang F, Sahu V, Peng K, et al. Recurrent RhoGAP gene fusion CLDN18-ARHGAP26 promotes RHOA activation and focal adhesion kinase and YAP-TEAD signalling in diffuse gastric cancer. Gut. 2024. PMID: 38621923. doi:10.1136/gutjnl-2023-329686
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。